KPKatharine Andress Rowe Price

Katharine Andress Rowe Price

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Katharine Andress Rowe Price has a total of 139 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Durable response to tipifarnib in a patient with refractory head and neck cancer with a HRAS mutation: A case report

    by Jennifer J Gile, Katharine Price, Binav Baral, Thomas E Witzig

    Introduction: Head and neck squamous cell carcinoma (HNSCC) remains a clinically challenging malignancy, particularly in the recurrent or metastatic setting after progression on multimodality therapy. Activating health reimbursement arrangement (HRAS) mutations occur in approximately 4–8% of HNSCC and represent a potentially actionable target. Tipifarnib, an oral farnesyltransferase inhibitor, has demonstrated promising activity in HRAS-mutant tumors but is not commercially available despite prior Breakthrough Therapy designation. Case Report: We report the case of a 48-year-old woman with recurrent, treatment-refractory oral cavity squamous cell carcinoma who experienced a dramatic and durable response to tipifarnib. Following initial treatment, she developed rapid locoregional recurrence requiring tracheostomy. Her disease progressed through multiple lines of therapy. Comprehensive next-generation sequencing of recurrent tumor tissue revealed an HRAS mutation. Given lack of response to prior checkpoint inhibitors, compassionate use of tipifarnib was initiated. The patient experienced a near-complete response within two months and achieved a complete response by 12 months and continues to remain disease free almost two years after therapy initiation with excellent functional recovery and manageable toxicity limited primarily to neutropenia. Conclusion: This case highlights the transformative potential of precision oncology in refractory HNSCC. Broader access to HRAS-targeted therapies and prospective validation of molecular predictors are urgently needed to improve outcomes in this molecularly defined subset.

  • Phase II Trial of Pemetrexed and Pembrolizumab in Patients With Recurrent and/or Metastatic Nonadenoid Cystic Salivary Gland Cancer

    by Katharine Andress Rowe Price, Nathan Foster, Erik Asmus, Harry Fuentes-Bayne, Casey Fazer-Posorske, Jordan Meyers, Panayiotis Savvides, Yujie Zhao, Patrick McGarrah, Anna Nguyen, et al.

    PURPOSE: Treatment options for patients with recurrent/metastatic (R/M) salivary gland cancer (SGC) are limited. Limited preclinical and clinical data suggested benefit of pemetrexed in patients with R/M SGC but, to our knowledge, no prospective data exist. We conducted a phase II trial of the combination of pemetrexed and pembrolizumab in patients with R/M SGC; results from the nonadenoid cystic carcinoma (ACC) cohort are reported. PATIENTS AND METHODS: MC200708 is a phase II study of pemetrexed and pembrolizumab in patients with R/M SGC (ClinicalTrials.gov identifier: NCT04895735 ). Simon's two-stage design was used. Any number of prior therapies were allowed. Primary end point was overall response rate (ORR). Secondary end points included progression-free survival (PFS), overall survival (OS), and toxicity. All patients received pemetrexed 500 mg/m 2 IV once every 3 weeks and pembrolizumab 200 mg IV once every 3 weeks until progression or treatment intolerance. RESULTS: Twenty-five patients were enrolled; 24 were eligible and treated. Nine of 24 patients had a confirmed response for ORR of 37.5% (95% CI, 18.8 to 59.4). The ORR for patients with salivary duct carcinoma (SDC) was 63.6%. Median duration of response was 15.3 months (95% CI, 12.4 to not reached). Median OS was 20.0 months (95% CI, 17.1 to not reached) and median PFS was 6.2 months (95% CI, 2.1 to 17.3). One-year OS and PFS rates were 71.9% (95% CI, 55.0 to 94.0) and 36.1% (95% CI, 21.0 to 62.2), respectively. Seven patients (29.2%) had ≥1 grade 3 to 4 toxicity, the majority hematologic. The five patients with grade 3 to 4 nonhematologic toxicity had grade 3 fatigue, rash, heart failure, hematuria, mastoiditis, and hypokalemia. CONCLUSION: Pemetrexed and pembrolizumab has promising and durable activity in patients with R/M SGC, with notable responses in patients with SDC.

  • Open Access

    Induction Cisplatin, Docetaxel, and 5-Fluorouracil Versus Platinum Doublet in Human Papillomavirus-Associated Oropharyngeal Cancer

    by Ashwin Ganti, Patrick W. McGarrah, Harry Fuentes Bayne, Casey Fazer-Posorske, Binav Baral, Daniel J. Ma, Scott C. Lester, David M. Routman, Michelle A. Neben-Wittich, Jessica M. Wilson, et al.

    Management of locoregionally advanced human papillomavirus-positive oropharyngeal squamous cell carcinoma (HPV(+) OPSCC) can include induction chemotherapy followed by definitive chemoradiation. The standard induction regimen of cisplatin, docetaxel, and 5-fluorouracil (TPF) is associated with high toxicity. Given the chemosensitivity of HPV(+) OPSCC, platinum doublets are frequently used as induction therapy with potentially less toxicity. This retrospective study aimed to compare outcomes between treatment-naive HPV(+) OPSCC patients receiving induction TPF and those receiving an induction platinum doublet. Data collected included tumor characteristics, response after chemoradiation, hospitalization rates, and overall survival (OS). Fifty-five patients (18 TPF and 37 platinum doublet) were included. There was no significant difference in response after completion of definitive chemoradiation (TPF: CR 83.3%, PR 5.6%, progression or metastasis 11.1% vs. platinum doublet: CR 75.7%, PR 16.2%, progression or metastasis 8.1%; p = 0.5241). There were also no differences in hospitalizations for adverse events (38.9% in TPF vs. 40.5% in platinum doublet, p = 0.907) or recurrence (11.1% in TPF vs. 2.7% in platinum doublet, p = 0.198). The 5-year OS was 84.6% in the TPF group and 81.5% in the platinum doublet group (p = 0.581). Induction platinum doublet regimens offer comparable OS, response, and hospitalization rates to TPF in locally advanced HPV(+) OPSCC. Induction with a platinum doublet may be a viable de-escalation strategy for patients who are not candidates for TPF.

  • Navigating skin toxicity in the era of immunotherapy

    by Casey Fazer-Posorske, Anna Ms Schwecke, Lisa Msn Kottschade, Katharine Price

    Immunotherapy continues to revolutionize cancer treatment, instilling optimism and enhancing prognoses across diverse malignancies. Immune checkpoint inhibitors (ICIs), including cytotoxic T lymphocyte–associated-protein 4 (CTLA-4), programmed death receptor 1 (PD-1), programmed death ligand 1 (PD-L1), and lymphocyte activation gene 3 (LAG-3) represent a paradigm shift. However, these transformative therapies introduce immune-related adverse events (irAEs), distinct from conventional cancer treatments, with delayed onset and potential persistence. While most cutaneous irAEs are mild, severe toxicity can occur, underscoring the importance of early detection and effective management. Cutaneous toxicities linked to ICIs manifest as various skin eruptions, affecting up to 71.5% of cases. The presentation is varied, including maculopapular rash, pruritus, psoriasiform, eczematous, and lichenoid dermatoses, with severe cases like Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS). Recognizing and managing ICI cutaneous toxicity is crucial for optimizing these life-saving cancer treatments. Export


  • Open Access

    Qualitative Study of Health Care Professional Perspectives on Recruiting Minority Patients in Cancer Trials

    by Katharine A. Price, Rahma Warsame, Elhadji A. Toure, Molly O’SHea, Yong-Hun Kim, Sara A. Ellingson, Joselle M. Cook, Gladys B. Asiedu

    Background: Underrepresented minority (URM) patients enroll in cancer clinical trials at low rates. We studied the perspectives of health care professionals to better understand the challenges and potential facilitators of recruiting URM patients into clinical trials. Methods: A purposeful sampling approach was utilized to recruit health care professionals and clinical research staff who recruited and cared for URM patients in a therapeutic cancer clinical trial at any Mayo Clinic site, from July 2018 through October 2021.Data were gathered using a semistructured qualitative interviews. Participants were interviewed about the challenges of recruiting URM patients into cancer clinical trials and possible strategies for improving URM patient enrollment. Data were analyzed using a thematic analysis. Results: Of the key themes that emerged from participant interviews ( n = 28), perceived barriers to recruiting URM patients into clinical trials included lack of workforce diversity, underutilization of patient navigators, ineffective community outreach and patient recruitment, restricted access to diverse patient populations, and restrictive clinical trial eligibility criteria. Other barriers reported were lack of insurance and access to care and transportation, low socioeconomic status, and mistrust of health care and research. Strategies suggested for improving the recruitment of URM patients into clinical trials included: diversifying and adding research staff, increasing and improving community outreach and advocacy, partnering with clinics closer to patients, increasing monetary and logistical support for patient participation, creating opportunities that build and enhance trust, and systematically examining and modifying clinical trial eligibility criteria. Conclusions: Our findings reveal barriers that have limited URM patient inclusion in cancer clinical trials and highlight strategies to overcoming these barriers.


  • Open Access

    Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT study

    by Kevin C Flanagan, Jon Earls, Jeffrey Hiken, Rachel L Wellinghoff, Michelle M Ponder, Howard L McLeod, William H Westra, Vera Vavinskaya, Leisa Sutton, Ida Deichaite, et al.

    Background Despite advances in cancer care and detection, >65% of patients with squamous cell cancer of the head and neck (HNSCC) will develop recurrent and/or metastatic disease. The prognosis for these patients is poor with a 5-year overall survival of 39%. Recent treatment advances in immunotherapy, including immune checkpoint inhibitors like pembrolizumab and nivolumab, have resulted in clinical benefit in a subset of patients. There is a critical clinical need to identify patients who benefit from these antiprogrammed cell death protein 1 (anti-PD-1) immune checkpoint inhibitors. Methods Here, we report findings from a multicenter observational study, PREDicting immunotherapy efficacy from Analysis of Pre-treatment Tumor biopsies (PREDAPT), conducted across 17 US healthcare systems. PREDAPT aimed to validate OncoPrism-HNSCC, a clinical biomarker assay predictive of disease control in patients with recurrent or metastatic HNSCC treated with anti-PD-1 immune checkpoint inhibitors as a single agent (monotherapy) and in combination with chemotherapy (chemo-immunotherapy). The test used RNA-sequencing data and machine learning models to score each patient and place them into groups of low, medium, or high. Results The OncoPrism-HNSCC prediction significantly correlated with disease control in both the monotherapy cohort (n=62, p=0.004) and the chemo-immunotherapy cohort (n=50, p=0.01). OncoPrism-HNSCC also significantly predicted progression-free survival in both cohorts (p=0.015 and p=0.037, respectively). OncoPrism-HNSCC had more than threefold higher specificity than programmed death-ligand 1 combined positive score and nearly fourfold higher sensitivity than tumor mutational burden for predicting disease control. Conclusions Here, we demonstrate the clinical validity of the OncoPrism-HNSCC assay in identifying patients with disease control in response to anti-PD-1 immune checkpoint inhibitors. Trial registration number NCT04510129.


  • Open Access

    A Mixed-Method Approach to Explore Successful Recruitment and Treatment of Minority Patients on Therapeutic Cancer Clinical Trials at a Tertiary Referral Center Using Photo-Elicitation Interviews

    by Katharine A.R. Price, Rahma Warsame, Mary O'SHea, Yonghun Kim, Sara A. Ellingson, Gladys B. Asiedu

    Introduction: Under-represented minority patients (URM) enroll in cancer clinical trials (CCT) at low rates. To gain insight into barriers and facilitators to CCT enrollment, we conducted a mixed method study of URM patients who were successfully treated on a therapeutic CCT from 2018–2021 at all institutional sites. Methods: A retrospective chart review of 270 minority patients was conducted to identify patient demographics and characteristics. All living URM patients were requested to participate in a survey and qualitative interview using a photo elicitation technique. Results: Most patients who participated in a CCT were patients with solid tumors, metastatic disease, and did not live in a rural area. Survey data showed that the two most significant drivers of CCT enrollment were potential of benefit to self and to others (altruism). Direct recommendation from a healthcare provider to participate in CCT was critical. URM patients enrolled on a CCT experience a significant burden of symptoms and financial distress. Key themes identified from the interviews that motivated patients to participate included chance for cure, staying positive, altruism and advancement of science, and having diverse representation in research. Patient-level facilitators to participation included social support, cost coverage, and limited treatment options. Sytematic facilitators identified included minimizing logistical barriers, decentralizing cancer clinical trials, increasing awareness via patient narratives, diversifying research staff, minimizing cost, and being clear on puropose and benefit of the trial. Conclusion: Success stories of minority recruitment can provide useful information to enhance minority accrual. Photo elicitation interviews provide rich narratives of patient experience.


  • Capecitabine for Salvage Treatment of Patients With Heavily Pretreated Human Papillomavirus–Associated Oropharynx Cancer With Distant Metastases

    by Pa-C Anna C. Cooper, Pa-C Casey A. Fazer, Mbbs Ashish V. Chintakuntlawar, Harry E. Fuentes Bayne, Patrick W. McGarrah, Katharine A. R. Price

    Patients with metastatic human papillomavirus-associated oropharyngeal cancer (HPV-OPC) have a median overall survival exceeding 2 years and are often candidates for multiple lines of palliative therapy. With the approval of immunotherapy as first-line treatment, salvage therapeutic options are limited. We describe our experience using capecitabine as salvage therapy for patients with recurrent or metastatic (R/M) HPV-OPC. We performed a retrospective study of patients with R/M HPV-OPC with distant metastatic disease. Eligible patients were identified from a medical oncology clinical database. Demographic and clinical data were abstracted from the medical record. Survival probabilities were estimated with the Kaplan-Meier method. 10 patients were identified. Sites of metastatic disease included lung, liver, mediastinal lymph nodes, bone, abdominal lymph nodes, and soft tissue. Most patients received capecitabine as fourth-line treatment. The median duration from start of capecitabine therapy until death was 10.5 months. Best treatment response was as follows: partial responses (PR) were seen in 4 of 10 (40%), stable disease (SD) in 3 of 10 (30%), and progressive disease (PD) in 2 of 10 (20%). The clinical benefit rate (CR + PR + SD) was 70%. Reasons for discontinuation included disease progression (n = 8) and side effects (n = 2). One patient notably had prolonged benefit from capecitabine and continued to be on treatment for 34 months total. Capecitabine is a potential salvage treatment for heavily pretreated patients with R/M HPV-OPC, with some patients experiencing prolonged response. Clinical or molecular predictors of response would be helpful to identify patients likely to benefit; a larger prospective study would be useful to confirm efficacy in this patient population.

  • Open Access

    Long-Term Toxic Effects, Swallow Function, and Quality of Life on MC1273: A Phase 2 Study of Dose De-escalation for Adjuvant Chemoradiation in Human Papillomavirus-Positive Oropharyngeal Cancer

    by Katharine Price, Kathryn M. Van Abel, Eric J. Moore, Samir H. Patel, Michael L. Hinni, Ashish V. Chintakuntlawar, Darlene Graner, Michelle Neben-Wittich, Yolanda I. Garces, Daniel L. Price, et al.


  • Open Access

    Emerging Disparities in Prevention and Survival Outcomes for Patients with Head and Neck Cancer and Recommendations for Health Equity

    by Manisha Salinas, Ashish Chintakuntlawar, Ivie Arasomwan, Ahmed Eltahir, Katharine A. R. Price

    Purpose of Review: The aim of this review is to describe less known and emerging disparities found in the prevention and survival outcomes for patients with head and neck cancer (HNC) that are likely to play an increasingly important role in HNC outcomes and health inequities. Recent Findings: The following factors contribute to HNC incidence and outcomes: (1) the effect of rurality on prevention and treatment of HNC, (2) dietary behavior and nutritional factors influencing the development of and survival from HNC, and (3) barriers and benefits of telehealth for patients with HNC. Summary: Rurality, nutrition and diet, and telehealth usage and access are significant contributors to the existing health disparities associated with HNC. Population and culturally specific interventions are urgently needed as well as more research to further define the issues and develop appropriate population and individual level solutions.